Excellence in Innovation

Summary of work

Takeda is a leader in haematology (bleeding disorders), with a long heritage backed by decades of real-world experience. Together with the haematology community, we are raising expectations for the future, including earlier diagnosis and more personalised patient care.

In this pursuit of personalised care, Takeda has launched myPKFiT™, a global platform, developed and regulated as two medical devices:

• myPKFiT™ for Healthcare Professionals (web-based physician platform)
• myPKFiT™ for Patients (mobile app).

The myPKFiT™ physician platform helps to determine the personalised dosing regimen for people living with moderate or severe haemophilia A who require clotting factor VIII (FVIII) replacement. The platform then generates a QR code which enables patients to access and activate the myPKFiT™ mobile app for their use. Once activated, the app serves as a digital logbook, making it convenient to record bleed and infusion events, and track estimated FVIII levels in ’real-time’ following a prophylactic infusion (injecting FVIII into the blood), which is one of its main innovative features.

Judges' comments

The myPKFiT mobile app demonstrated clear innovation in terms of supporting personalised treatment. There was also quick recognition from the HCP community – a clear breakthrough innovation.